Epidemiología de la varicela en España en los períodos pre y post vacunación

Peña-Rey, I.; Aragón, M.V. Martínez de; Hueso, Ana Villaverde; Arellano, M. Terrés; Cabero, Enrique Alcalde; Rodríguez, Berta Suárez

doi:10.1590/s1135-57272009000500012

Cited by 23 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2005, the vaccine was marketed and parents started to give it to their children, so it is difficult to establish accurate vaccine coverage rates in our records. 3 Based on our data, the greater percentage of hospitalizations per number of cases (1%) was recorded in 2005, which was also the year when the greatest hospitalization expenses were incurred. This is suggestive of a greater virulence.…”

Section: Discussionmentioning

confidence: 74%

“…Once hospitalizations for this cause in the Aragón community are analyzed, 3 it is observed that more than half of cases occurred in children younger than 5 years old; therefore, it is expected that health expenses will decrease following the first years of the immunization campaign as long as coverage is high.…”

Section: Discussionmentioning

confidence: 99%

“…3 A reduction in hospital discharges has been recorded in the autonomous communities where infants have been vaccinated. 12 Our study also observed that hospital discharges reduced to almost a half as of 2008 (with the vaccine already in the market) compared to previous years.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5]7 Outbreaks in schools have been observed with a single dose and coverage close to 99%. 5 Also with a single dose, the age of varicella onset may be delayed.…”

Section: Discussionmentioning

confidence: 99%

“…It was later approved for its general use in South Korea (1988), the United States, Sweden, and Germany (1995). 3 In Spain, it has been used in hospitals since 1997 and approved for sale at pharmacies in 2005. At present, in Spain, there are two live, attenuated virus (OKA strain) vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A cost-benefit analysis of varicella vaccination in Aragón

Blasco

Pérez-Aramendía

2017

Arch Argent Pediat

View full text Add to dashboard Cite

Background. Varicella, a contagious and infectious disease that is usually benign in children, may become complicated among adults and vulnerable children and may even be life-threatening. There are effective vaccines. A retrospective study was conducted about costs and resulting hospitalizations related to this disease in the population of Aragón in the 2004-2014 period. Costs were compared to the expenses that would have been incurred if those people had received the vaccine and also to the expenses of vaccinating the 1-year-old population over the entire period. A cost-benefit analysis was done to assess the economic impact of varicella vaccination. Method. Data for the 11-year period were provided by the Autonomous Community of Aragón (Spain) and included annual varicella incidence, hospital discharges of varicella cases, costs of primary health care visits and hospitalizations for each year, costs of each workday as per the minimum annual salary and of drugs used). Capitalized costs were estimated and compared to capitalized expenses of vaccination, and a sensitivity analysis was performed. Results. A benefit-cost ratio of 1.6 was obtained considering that all children who had varicella had been vaccinated and had received a booster dose. A benefit-cost ratio of 1.24 was obtained considering that the vaccine had been administered to every 1-year-old individual at a price of EUR 28.59 per vaccine. Over the 11-year period, 53% of hospitalizations corresponded to children younger than 5 years old. Conclusions. Public campaigns for the immunization of children younger than 4 years old with 2 doses lead to cost savings and are cost-effective because the vaccine price results in a benefit-cost ratio greater than 1. A major reduction is expected in the number of hospitalizations among children aged 3-4 years.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5]7 Outbreaks in schools have been observed with a single dose and coverage close to 99%. 5 Also with a single dose, the age of varicella onset may be delayed.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations